New developments and standard of care in the management of advanced gastric cancer - ScienceDirect
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
Novel oral chemotherapeutic holds potential for stomach cancer patients
Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Department of Gastrointestinal Oncology
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
Ongoing Clinical Studies to Investigate Trifluridine/Tipiracil in... | Download Scientific Diagram
Result of the PII trial of TAS-102 in third/fourth line colorectal... | Download Scientific Diagram
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm | Nature Reviews Clinical Oncology
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Frontiers | Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer - YouTube
Later Lines of Therapy in Metastatic Gastric Cancer
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
